nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

15. Magnetic Nanoparticles Used as Contrast Agents in MRI: Relaxometric Characterisation

verfasst von : Marc-André Fortin

Erschienen in: Magnetic Characterization Techniques for Nanomaterials

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Magnetic resonance imaging (MRI) has developed at an exponential rate over the last decades, and the development of contrast agents to enhance the visualization of organs has followed the same trend. Meanwhile, magnetic nanoparticles that generate either “positive” or “negative” contrast in MRI have become one of the most important biomedical applications of nanotechnology. Indeed, superparamagnetic iron oxide nanoparticles, as negative contrast agents for T ₂/T ₂ ^*-weighted imaging, have found numerous applications in preclinical and clinical MRI (cell labeling, vascular contrast, lymph node imaging, liver contrast). In addition to this, paramagnetic and antiferromagnetic nanoparticles based on the elements Gd³⁺ and Mn²⁺ have mainly been exploited in vascular procedures and targeted imaging, for their capacity to enhance the MR signal of blood and of molecular signatures of endovascular disease. They are commonly referred to as “positive” contrast agents for T ₁-weighted imaging.

The present chapter is an introduction to the fundamental principles of nanoparticle-based MRI contrast agents. It addresses the main considerations guiding the relaxometric characterization of aqueous suspensions of magnetic nanoparticles, based on the elements iron, manganese, and gadolinium (Fe, Mn, Gd). The relaxivity of MRI contrast agents depends on their nanoparticulate structure, on their magnetic properties, on the distance between water molecules and their surface, and on the kinetics and rotational rate of the compound in biological fluids and in tissues. Among the main parameters guiding the relaxation time of water protons in the vicinity of contrast agents, figure the number of water molecules bound to the contrast agent, the size of the nanocrystals, the total hydrodynamic diameter of nanoparticles, their rotational correlation time, and the exchange rate between the water and the nanoparticle surface.

The general magnetic and relaxometric characteristics of the major classes of nanoparticles used as MRI contrast agents will be reviewed. Examples of nuclear magnetic relaxation dispersion profiles (NMRD), revealing the relaxometric potential of magnetic particles at increasing magnetic field strengths, are also presented and discussed.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Magneto-Optical (MO) Characterization Tools for Chemically Prepared Magnetic Nanomaterials

Stark DD, Bradley WG (1999) Magnetic resonance imaging, 3rd edn. C.V.Mosby, St-Louis, p 44

Bushberg JT (2012) The essential physics of medical imaging. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia

Hashemi RH, Bradley WG, Lisanti CJ (2010) Ovid Technologies Inc. MRI the basics. Lippincott Williams & Wilkins, Philadelphia, p ix, 385 p

Caravan P (2006) Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35:512–523CrossRef

Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352CrossRef

Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715–724CrossRef

Merbach AS, Helm L,Tόth E (2013) The chemistry of contrast agents in medical magnetic resonance imaging. Wiley, Hoboken, p 1 texte électronique (514 p)

Faucher L, Gossuin Y, Hocq A, Fortin MA (2011) Impact of agglomeration on the relaxometric properties of paramagnetic ultra-small gadolinium oxide nanoparticles. Nanotechnology 22:295103CrossRef

Faucher L, Tremblay M, Lagueux J, Gossuin Y, Fortin MA (2012) Rapid synthesis of PEGylated ultrasmall gadolinium oxide nanoparticles for cell labeling and tracking with MRI. ACS Appl Mater Interfaces 4:4506–4515CrossRef

10.

Letourneau M, Tremblay M, Faucher L, Rojas D, Chevallier P, Gossuin Y, Lagueux J, Fortin MA (2012) MnO-labeled cells: positive contrast enhancement in MRI. J Phys Chem B 116:13228–13238CrossRef

11.

Naccache R, Chevallier P, Lagueux J, Gossuin Y, Laurent S, Vander Elst L, Chilian C, Capobianco JA, Fortin MA (2013) High relaxivities and strong vascular signal enhancement for NaGdF4 nanoparticles designed for dual MR/optical imaging. Adv Healthc Mater 2:1478–1488CrossRef

12.

Bridot JL, Faure AC, Laurent S, Riviere C, Billotey C, Hiba B, Janier M, Josserand V, Coll JL, Vander Elst L, Muller R, Roux S, Perriat P, Tillement O (2007) Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 129:5076–5084CrossRef

13.

Na HB, Hyeon T (2009) Nanostructured T1 MRI contrast agents. J Mater Chem 19:6267–6273CrossRef

14.

Park JY, Baek MJ, Choi ES, Woo S, Kim JH, Kim TJ, Jung JC, Chae KS, Chang Y, Lee GH (2009) Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T-1 MR1 contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T-1 MR images. ACS Nano 3:3663–3669CrossRef

15.

Faucher L, Guay-Bégin AA, Lagueux J, Côté MF, Petitclerc E, Fortin MA (2011) Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging 6:209–218

16.

Grobner T, Prischl FC (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72:260–264CrossRef

17.

Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654–668CrossRef

18.

Na HB, Song IC, Hyeon T (2009) Inorganic nanoparticles for MRI contrast agents. Adv Mater 21:2133–2148CrossRef

19.

Engström M, Klasson A, Pedersen H, Vahlberg C, Käll PO, Uvdal K (2006) High proton relaxivity for gadolinium oxide nanoparticles. MAGMA 19:180–186CrossRef

20.

Ahren M, Selegard L, Klasson A, Soderlind F, Abrikossova N, Skoglund C, Bengtsson T, Engström M, Käll PO, Uvdal K (2010) Synthesis and characterization of PEGylated Gd2O3 nanoparticles for MRI contrast enhancement. Langmuir 26:5753–5762CrossRef

21.

Zhou J, Yu MX, Sun Y, Zhang XZ, Zhu XJ, Wu ZH, Wu DM, Li FY (2011) Fluorine-18-labeled Gd³⁺/Yb³⁺/Er³⁺ co-doped NaYF4 nanophosphors for multimodality PET/MR/UCL imaging. Biomaterials 32:1148–1156

22.

Cheung ENM, Alvares RDA, Oakden W, Chaudhary R, Hill ML, Pichaandi J, Mo GCH, Yip C, Macdonald PM, Stanisz GJ, van Veggel FCJM, Prosser RS (2010) Polymer-stabilized lanthanide fluoride nanoparticle aggregates as contrast agents for magnetic resonance imaging and computed tomography. Chem Mater 22:4728–4739CrossRef

23.

Chen GY, Ohulchanskyy TY, Law WC, Agren H, Prasad PN (2011) Monodisperse NaYbF4: Tm3+/NaGdF4 core/shell nanocrystals with near-infrared to near-infrared upconversion photoluminescence and magnetic resonance properties. Nanoscale 3:2003–2008CrossRef

24.

Na HB, Lee JH, An K, Park YI, Park M, Lee IS, Nam DH, Kim ST, Kim SH, Kim SW, Lim KH, Kim KS, Kim SO, Hyeon T (2007) Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl 46:5397–5401CrossRef

25.

Schladt TD, Schneider K, Shukoor MI, Natalio F, Bauer H, Tahir MN, Weber S, Schreiber LM, Schroder HC, Muller WEG, Tremel W (2010) Highly soluble multifunctional MnO nanoparticles for simultaneous optical and MRI imaging and cancer treatment using photodynamic therapy. J Mater Chem 20:8297–8304CrossRef

26.

Simon GH, Von Vopelius-Feldt J, Fu Y, Schlegel J, Pinotek G, Wendland MF, Chen MH, Daldrup-Link HE (2006) Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol 41:45–51CrossRef

27.

Koretsky AP, Silva AC (2004) Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 17:527–531CrossRef

28.

Lee JH, Koretsky AP (2004) Manganese enhanced magnetic resonance imaging. Curr Pharm Biotechnol 5:529–537CrossRef

29.

Sosnovik DE, Nahrendorf M, Weissleder R (2008) Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol 103:122–130CrossRef

30.

Corot C, Robert P, Idee JM, Port M (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 58:1471–1504CrossRef

31.

Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A (2009) Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:299–310CrossRef

32.

Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108:2064–2110CrossRef

33.

Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 152:167–173CrossRef

34.

Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C (2007) Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomed 2:609–622

35.

Sun S, Zeng H (2002) Size-controlled synthesis of magnetite nanoparticles. J Am Chem Soc 124:8204–8205CrossRef

36.

Stephen ZR, Kievit FM, Zhang M (2011) Magnetite nanoparticles for medical MR imaging. Mater Today 14:330–338CrossRef

37.

Wu W, He Q, Jiang C (2008) Magnetic iron oxide nanoparticles: synthesis and surface functionalization strategies. Nanoscale Res Lett 3:397–415CrossRef

38.

Schladt TD, Schneider K, Schild H, Tremel W (2011) Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 40:6315–6343CrossRef

39.

Rui H, Xing R, Xu Z, Hou Y, Goo S, Sun S (2010) Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater 22:2729–2742CrossRef

40.

Lu AH, Salabas EL, Schuth F (2007) Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem 46:1222–1244CrossRef

41.

Jolivet JP, Chanéac C, Tronc E (2004) Iron oxide chemistry. From molecular clusters to extended solid networks. Chem Commun 10:481–487

42.

Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021CrossRef

43.

Bee A, Massart R, Neveu S (1995) Synthesis of very fine maghemite particles. J Magn Magn Mater 149:6–9CrossRef

44.

Wormuth K (2001) Superparamagnetic latex via inverse emulsion polymerization. J Colloid Interface Sci 241:366–377CrossRef

45.

Si S, Kotal A, Mandal TK, Giri S, Nakamura H, Kohara T (2004) Size-controlled synthesis of magnetite nanoparticles in the presence of polyelectrolytes. Chem Mater 16:3489–3496CrossRef

46.

Wan S, Huang J, Yan H, Liu K (2006) Size-controlled preparation of magnetite nanoparticles in the presence of graft copolymers. J Mater Chem 16:298–303CrossRef

47.

Gonzales M, Krishnan KM (2005) Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mater 293:265–270CrossRef

48.

Giri J, Guha Thakurta S, Bellare J, Kumar Nigam A, Bahadur D (2005) Preparation and characterization of phospholipid stabilized uniform sized magnetite nanoparticles. J Magn Magn Mater 293:62–68CrossRef

49.

Sun YK, Ma M, Zhang Y, Gu N (2004) Synthesis of nanometer-size maghemite particles from magnetite. Colloids Surf A Physicochem Eng Asp 245:15–19CrossRef

50.

Park J, An KJ, Hwang YS, Park JG, Noh HJ, Kim JY, Park JH, Hwang NM, Hyeon T (2004) Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater 3:891–895CrossRef

51.

De Cuyper M, Joniau M (1988) Magnetoliposomes. Formation and structural characterization. Eur Biophys J 15:311–319CrossRef

52.

Fievet F, Lagier JP, Blin B, Beaudoin B, Figlarz M (1989) Homogeneous and heterogeneous nucleations in the polyol process for the preparation of micron and submicron size metal particles. Solid State Ion 32–33:198–205CrossRef

53.

Tzitzios VK, Petridis D, Zafiropoulou I, Hadjipanayis G, Niarchos D (2005) Synthesis and characterization of L10 FePt nanoparticles from Pt-Fe3O4 core-shell nanoparticles. J Magn Magn Mater 294:e95–e98CrossRef

54.

Sra AK, Ewers TD, Schaak RE (2005) Direct solution synthesis of intermetallic AuCu and AuCu3 nanocrystals and nanowire networks. Chem Mater 17:758–766CrossRef

55.

Joseyphus RJ, Kodama D, Matsumoto T, Sato Y, Jeyadevan B, Tohji K (2007) Role of polyol in the synthesis of Fe particles. J Magn Magn Mater 310:2393–2395CrossRef

56.

Hu F, MacRenaris KW, Waters EA, Liang T, Schultz-Sikma EA, Eckermann AL, Meade TJ (2009) Ultrasmall, water-soluble magnetite nanoparticles with high relaxivity for magnetic resonance imaging. J Phys Chem C 113:20855–20860CrossRef

57.

Bazzi R, Flores-Gonzalez MA, Louis C, Lebbou K, Dujardin C, Brenier A, Zhang W, Tillement O, Bernstein E, Perriat P (2003) Synthesis and luminescent properties of sub-5-nm lanthanide oxides nanoparticles. J Lumin 102:445–450CrossRef

58.

Söderlind F, Pedersen H, Petoral RM, Käll PO, Uvdal K (2005) Synthesis and characterisation of Gd2O3 nanocrystals functionalised by organic acids. J Colloid Interf Sci 288:140–148CrossRef

59.

Park JY, Choi ES, Baek MJ, Lee GH, Woo S, Chang Y (2009) Water-soluble ultra small paramagnetic or superparamagnetic metal oxide nanoparticles for molecular MR imaging. Eur J Inorg Chem 2477–2481. doi:10.1002/ejic.200900173

60.

Naccache R, Vetrone F, Mahalingam V, Cuccia LA, Capobianco JA (2009) Controlled synthesis and water dispersibility of hexagonal phase NaGdF4:Ho³⁺/Yb³⁺ nanoparticles. Chem Mater 21:717–723

61.

Vetrone F, Naccache R, Mahalingam V, Morgan CG, Capobianco JA (2009) The active-core/active-shell approach: a strategy to enhance the upconversion luminescence in lanthanide-doped nanoparticles. Adv Funct Mater 19:2924–2929CrossRef

62.

Wong HT, Vetrone F, Naccache R, Chan HLW, Hao JH, Capobianco JA (2011) Water dispersible ultra-small multifunctional KGdF4:Tm³⁺, Yb³⁺ nanoparticles with near-infrared to near-infrared upconversion. J Mater Chem 21:16589–16596

63.

Morales MA, Skomski R, Fritz S, Shelburne G, Shield JE, Yin M, O’Brien S, Leslie-Pelecky DL (2007) Surface anisotropy and magnetic freezing of MnO nanoparticles. Phys Rev B 75:134423

64.

Bertin A, Michou-Gallani AI, Gallani JL, Felder-Flesch D (2010) In vitro neurotoxicity of magnetic resonance imaging (MRI) contrast agents: influence of the molecular structure and paramagnetic ion. Toxicol In Vitro 24:1386–1394CrossRef

65.

Bertin A, Steibel J, Michou-Gallani AI, Gallani JL, Felder-Flesch D (2009) Development of a dendritic manganese-enhanced magnetic resonance imaging (MEMRI) contrast agent: synthesis, toxicity (in vitro) and relaxivity (in vitro, in vivo) studies. Bioconjug Chem 20:760–767CrossRef

66.

Sahoo Y, Goodarzi A, Swihart MT, Ohulchanskyy TY, Kaur N, Furlani EP, Prasad PN (2005) Aqueous ferrofluid of magnetite nanoparticles: fluorescence labeling and magnetophoretic control. J Phys Chem B 109:3879–3885CrossRef

67.

Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M (2002) Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging – preclinical in vivo characterization. Invest Radiol 37:167–177CrossRef

68.

Liu C, Huang PM (1999) Atomic force microscopy and surface characteristics of iron oxides formed in citrate solutions. Soil Sci Soc Am J 63:65–72CrossRef

69.

Daou TJ, PourroyG, Greneche JM, Bertin A, Felder-Flesch D, Begin-Colin S (2009) Water soluble dendronized iron oxide nanoparticles. Dalton Trans 23:4442–4449. doi:10.1039/b823187g

70.

Mornet S, Vasseur S, Grasset F, Duguet E (2004) Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem 14:2161–2175CrossRef

71.

McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY (1994) Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4:301–307CrossRef

72.

Bulte JWM, Kraitchman DL (2004) Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 17:484–499CrossRef

73.

Paul KG, Frigo TB, Groman JY, Groman EV (2004) Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Bioconjug Chem 15:394–401CrossRef

74.

Tiefenauer LX, Tschirky A, Kühne G, Andres RY (1996) In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson Imaging 14:391–402CrossRef

75.

Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318

76.

Papisov MI, Bogdanov A Jr, Schaffer B, Nossiff N, Shen T, Weissleder R, Brady TJ (1993) Colloidal magnetic resonance contrast agents: effect of particle surface on biodistribution. J Magn Magn Mater 122:383–386CrossRef

77.

Fortin MA, Petoral RM, Söderlind F, Klasson A, Engström M, Veres T, Käll PO, Uvdal K (2007) Polyethylene glycol-covered ultra-small Gd2O3 nanoparticles for positive contrast at 1.5 T magnetic resonance clinical scanning. Nanotechnology 18:395501 (395501–395509)CrossRef

78.

Faure AC, Dufort S, Josserand V, Perriat P, Coll JL, Roux S, Tillement O (2009) Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small 5:2565–2575CrossRef

79.

Shi ZL, Neoh KG, Kang ET, Shuter B, Wang SC (2010) Bifunctional Eu³⁺-doped Gd2O3 nanoparticles as a luminescent and T-1 contrast agent for stem cell labeling. Contrast Media Mol Imaging 5:105–111

80.

Klasson A, Ahren M, Hällquist E, Rosén A, Käll PO, Uvdal K, Engström M (2008) Positive MRI contrast enhancement in THP-1 cells with Gd2O3 nanoparticles. Contrast Media Mol Imaging 3:106–111CrossRef

81.

Faucher L, Tremblay M, Gossuin Y, Rojas D, Chevallier P, Lacroix S, Fortin M-A (2011) Ultra-small nanoclusters of GdOx: a new, efficient contrast agent for in vivo cell tracking studies in T1-w. MRI. In: WMI Society (ed) World Molecular Imaging Congress, San Diego

82.

Guay-Begin AA, Chevallier P, Faucher L, Turgeon S, Fortin MA (2011) Surface modification of gadolinium oxide thin films and nanoparticles using polyethylene glycol-phosphate. Langmuir ACS J Surf Colloid. doi:10.1021/la202780x

83.

Lamanna G, Kueny-Stotz M, Mamlouk-Chaouachi H, Ghobril C, Basly B, Bertin A, Miladi I, Billotey C, Pourroy G, Begin-Colin S, Felder-Flesch D (2011) Dendronized iron oxide nanoparticles for multimodal imaging. Biomaterials 32:8562–8573CrossRef

84.

Chevallier P, Walter A, Garofalo A, Veksler I, Lagueux J, Bégin-Colin S, Felder-Flesch D, Fortin M-A (2014) Tailored biological retention and efficient clearance of pegylated ultra-small MnO nanoparticles as positive MRI contrast agents for molecular imaging. J Mater Chem B 2:1779–1790

85.

Banci L, Bertini L, Luchinat C (1991) Nuclear and electron relaxation. The magnetic nucleus-unpaired electron coupling in solution. In: Magnetic Resonance in Chemistry; Special issue: NMR in bioorganic chemistry. VCH, Ed, p S154

86.

Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF, Rubin DL, Zelch JV, Kuhlman JE, Outwater EK, Weinreb JC, Brown JJ, De Lange EE, Woodward PJ, Arildsen R, Foster GS, Runge VM, Aisen AM, Muroff LR, Thoeni RF, Parisky YR, Tanenbaum LN, Totterman S, Herfkens RJ, Knudsen J, Laster RE Jr, Duerinckx A, Stillman AE, Spritzer CE, Saini S, Rofsky NM, Bernardino ME (1999) A multisite phase iii study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. J Magn Reson Imaging 10:15–24CrossRef

87.

Rocklage SM, Cacheris WP, Quay SC, Ekkehardt Hahn F, Raymond KN (1989) Manganese(II) N, N′-dipyridoxylethylenediamine-N, N′-diacetate 5,5′-bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 28:477–485CrossRef

88.

O’Handley RC (2000) Modern magnetic materials: principles and applications. Wiley, New York

89.

Gossuin Y, Hocq A, Vuong QL, Disch S, Hermann RP, Gillis P (2008) Physico-chemical and NMR relaxometric characterization of gadolinium hydroxide and dysprosium oxide nanoparticles. Nanotechnology 19. http://journals.aps.org/prb/abstract/10.1103/PhysRevB.75.134423

90.

Muller RN, Vander Elst L, Roch A, Peters JA, Csajbok E, Gillis P, Gossuin Y (2006) Relaxation by metal-containing nanosystems. Adv Inorg Chem 57:239–292

91.

Cornell RM, Schwertmann U (1996) The iron oxides: structure, properties, reactions, occurrence, and uses. VCH, Weinheim/New York

92.

Neel L (1948) Magnetic properties of ferrites: ferrimagnetism and antiferromagnetism. Ann Phys Paris 3:137–198

93.

Crangle J (1991) Solid-state magnetism. Van Nostrand Reinhold, New YorkCrossRef

94.

Dormann JL (1981) Superparamagnetism phenomenon. Rev Phys Appl 16:275–301CrossRef

95.

Rosensweig RE (2002) Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater 252:370–374CrossRef

96.

Chantrell RW, Lyberatos A, El-Hilo M, O’Grady K (1994) Models of slow relaxation in particulate and thin film materials (invited). J Appl Phys 76:6407–6412CrossRef

97.

Dormann JL, Spinu L, Tronc E, Jolivet JP, Lucari F, D’Orazio F, Fiorani D (1998) Effect of interparticle interactions on the dynamical properties of γ-Fe2O3 nanoparticles. J Magn Magn Mater 183:L255–L260CrossRef

98.

Dormann JL, D’Orazio F, Lucari F, Tronc E, Prené P, Jolivet JP, Fiorani D, Cherkaoui R, Noguès M (1996) Thermal variation of the relaxation time of the magnetic moment of γ-Fe2O3 nanoparticles with interparticle interactions of various strengths. Phys Rev B Condens Matter 53:14291–14297CrossRef

99.

Bean CP, Livingston JD (1959) Superparamagnetism. J Appl Phys 30:120S

100.

Bloembergen NJ, Purcell EM, Pound RV (1948) Relaxation effects in nuclear magnetic resonance absorption. Phys Rev 73:679CrossRef

101.

Solomon I (1955) Relaxation processes in a system of two spins. Phys Rev 99:559–565CrossRef

102.

Solomon I, Bloembergen NJ (1956) Nuclear magnetic interactions in the HF molecule. J Chem Phys 25:261CrossRef

103.

Bloembergen NJ (1957) Proton relaxation times in paramagnetic solutions. J Chem Phys 27:573CrossRef

104.

Bloembergen NJ, Morgan NO (1961) Proton relaxation times in paramagnetic solutions. J Chem Phys 34:842CrossRef

105.

Burtea C, Laurent S, Vander Elst L, Muller RN (2008) Contrast agents: magnetic resonance. Handb Exp Pharmacol 135–165. doi:10.1007/978-3-540-72718-7_7

106.

Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA (2004) Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted F-19 nanoparticles. Magn Reson Med 52:1255–1262CrossRef

107.

Luz Z, Meiboom S (1964) Proton relaxation in dilute solutions of cobalt (II) and nickel (II) ions in methanol and the rate of methanol exchange of the solvation sphere. J Chem Phys 40:2686–2692CrossRef

108.

Swift TJ, Connick RE (1962) NMR-Relaxation mechanisms of O17 in aqueous solutions of paramagnetic cations and the lifetime of water molecules in the first coordination sphere. J Chem Phys 37:307–320CrossRef

109.

Noack F (1986) NMR field-cycling spectroscopy: principles and applications. Prog Nucl Magn Reson Spectrosc 18:171–276CrossRef

110.

Merbach AE, Tôth E (2001) The chemistry of contrast agents in medical magnetic resonance imaging. Wiley, Chichester/New York

111.

Freed JH (1978) Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T1 processes. J Chem Phys 68:4034–4037CrossRef

112.

Bulte JM, Vymazal J, Brooks RA, Pierpaoli C, Frank JA (1993) Frequency dependence of MR relaxation times. II. Iron oxides. J Magn Reson Imaging 3:641–648CrossRef

113.

Hwang JS, Rao KVS, Freed JH (1976) An electron spin resonance study of the pressure dependence of ordering and spin relaxation in a liquid crystalline solvent. J Phys Chem 80:1490–1501CrossRef

114.

Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2010) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications (vol 108, pg 2064, 2008). Chem Rev 110:2574–2574

115.

Vuong QL, Berret JF, Fresnais J, Gossuin Y, Sandre O (2012) A universal scaling law to predict the efficiency of magnetic nanoparticles as MRI T2-contrast agents. Adv Healthc Mater 1:502–512CrossRef

116.

Gossuin Y, Roch A, Muller RN, Gillis P (2002) An evaluation of the contributions of diffusion and exchange in relaxation enhancement by MRI contrast agents. J Magn Reson 158:36–42CrossRef

117.

Laprise-Pelletier M, Bouchoucha M, Lagueux J, Chevallier P, Lecomte R, Gossuin Y, Kleitz F, Fortin MA (2015) Metal chelate grafting at the surface of mesoporous silica nanoparticles (MSNs): physico-chemical and biomedical imaging assessment. J Mater Chem B 3:748–758CrossRef

118.

Koenig SH, Baglin C, Brown Iii RD, Brewer CF (1984) Magnetic field dependence of solvent proton relaxation induced by Gd³⁺ and Mn²⁺ complexes. Magn Reson Med 1:496–501

119.

Koenig SH, Baglin CM, Brown Iii RD (1985) Magnetic field dependence of solvent proton relaxation in aqueous solutions of Fe³⁺ complexes. Magn Reson Med 2:283–288

120.

Muller RN, Vallet P, Maton F, Roch A, Goudemant JF, Vander Elst L, Gillis P, Peto S, Moiny F, Van Haverbeke Y (1990) Recent developments in design, characterization, and understanding of MRI and MRS contrast media. Invest Radiol 25:S34–S36CrossRef

121.

Ouakssim A, Fastrez S, Roch A, Laurent S, Gossuin Y, Piérart C, Vander Elst L, Muller RN (2004) Control of the synthesis of magnetic fluids by relaxometry and magnetometry. J Magn Magn Mater 272–276:e1711–e1713CrossRef

122.

Roch A, Muller RN, Gillis P (1999) Theory of proton relaxation induced by superparamagnetic particles. J Chem Phys 110:5403–5411CrossRef

123.

Li W, Tutton S, Vu AT, Pierchala L, Li BSY, Lewis JM, Prasad PV, Edelman RR (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46–52CrossRef

124.

Jung CW, Jacobs P (1995) Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 13:661–674CrossRef

125.

Reimer P, Marx C, Rummeny EJ, Müller M, Lentschig M, Balzer T, Dietl KH, Sulkowski U, Berns T, Shamsi K, Peters PE (1997) SPIO-enhanced 2D-TOF MR angiography of the portal venous system: results of an intraindividual comparison. J Magn Reson Imaging 7:945–949CrossRef

126.

Modo MMJJ, Bulte JWM (2007) Molecular and cellular MR imaging. CRC Press, Boca RatonCrossRef

127.

Kellar KE, Fujii DK, Gunther WHH, Briley-Sæbø K, Bjørnerud A, Spiller M, Koenig SH (2000) NC 100150 injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging 11:488–494CrossRef

128.

Daldrup-Link HE, Kaiser A, Helbich T, Werner M, Bjørnerud A, Link TM, Rummeny EJ (2003) Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad Radiol 10:1237–1246CrossRef

129.

Taupitz M, Wagner S, Schnorr J, Kravec I, Pilgrimm H, Bergmann-Fritsch H, Hamm B (2004) Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol 39:394–405CrossRef

130.

Kim BH, Lee N, Kim H, An K, Park YI, Choi Y, Shin K, Lee Y, Kwon SG, Na HB, Park JG, Ahn TY, Kim YW, Moon WK, Choi SH, Hyeon T (2011) Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T 1 magnetic resonance imaging contrast agents. J Am Chem Soc 133:12624–12631CrossRef

131.

Sandiford L, Phinikaridou A, Protti A, Meszaros LK, Cui X, Yan Y, Frodsham G, Williamson PA, Gaddum N, Botnar RM, Blower PJ, Green MA, de Rosales RT (2013) Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging. ACS Nano 7:500–512CrossRef

Titel: Magnetic Nanoparticles Used as Contrast Agents in MRI: Relaxometric Characterisation
verfasst von: Marc-André Fortin
Verlag: Springer Berlin Heidelberg
Buch: Magnetic Characterization Techniques for Nanomaterials
Print ISBN: 978-3-662-52779-5

Electronic ISBN: 978-3-662-52780-1

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-52780-1_15

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht